Physician profile
John Estes
NPI 1811586779
$2,519.63
in general payments reported to CMS, 2019-2025
15 companies · $867 in 2025
The $867 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $467 · 2023: $410 · 2024: $548 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.72 | 2021-2025 | |
| Orexo US, INC. | $402.72 | 2021-2025 | Zubsolv |
| Indivior INC. | $259.35 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.51 | 2022-2025 | Caplyta |
| Braeburn INC. | $172.71 | 2023-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $145.77 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $80.07 | 2022 | |
| Exact Sciences Corporation | $64.76 | 2024-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $64.14 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.03 | 2021 | |
| Gilead Sciences, INC. | $44.83 | 2022-2023 | |
| Pfizer INC. | $30.76 | 2023 | |
| Pear Therapeutics (US), INC. | $30.46 | 2022 | |
| Amgen INC. | $18.03 | 2025 | Otezla, Repatha |
| Actelion Pharmaceuticals US, INC. | $17.77 | 2025 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.